1. Home
  2. PGEN vs AMPH Comparison

PGEN vs AMPH Comparison

Compare PGEN & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$3.96

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$21.80

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGEN
AMPH
Founded
1998
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
PGEN
AMPH
Price
$3.96
$21.80
Analyst Decision
Buy
Buy
Analyst Count
5
7
Target Price
$8.33
$29.29
AVG Volume (30 Days)
5.6M
393.8K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.03
Revenue
$230,981,000.00
$719,887,000.00
Revenue This Year
$1,115.92
$7.19
Revenue Next Year
$81.04
$4.76
P/E Ratio
N/A
$10.67
Revenue Growth
N/A
N/A
52 Week Low
$1.23
$17.03
52 Week High
$5.47
$31.26

Technical Indicators

Market Signals
Indicator
PGEN
AMPH
Relative Strength Index (RSI) 50.55 58.51
Support Level $3.49 $20.41
Resistance Level $4.44 $22.90
Average True Range (ATR) 0.31 0.75
MACD 0.02 0.41
Stochastic Oscillator 57.83 94.35

Price Performance

Historical Comparison
PGEN
AMPH

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: